ClinicalTrials.gg
WithdrawnNCT05080621Updated Jan 5, 2022

Ripretinib in Combination With Binimetinib in Patients With Gastrointestinal Stromal Tumor (GIST)

A Phase 1/2 interventional study of Ripretinib and binimetinib in Gastrointestinal Stromal Tumors, sponsored by Deciphera Pharmaceuticals, LLC. Withdrawn. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-01-05.

Sponsored by Deciphera Pharmaceuticals, LLC (part of Ono Pharmaceutical Co. Ltd) · Phase 1/2, Interventional, and Treatment

Why this study was withdrawn
The Sponsor decided to discontinue this study due to a corporate restructuring intended to prioritize clinical development of select programs. No patients enrolled in this study and no patients received investigational product.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
0
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies in Gastrointestinal Stromal Tumors by Ono Pharmaceutical Co. Ltd — 2 open to participants now, 5 under way, 2 of them phase 3. Gastrointestinal Stromal Tumors · Ono Pharmaceutical Co. Ltd.

Started
2021
with 1 other
Phase 1/2
3 of 10
1 open now
Registered
6th of 10
by date

Among the 10 studies in Gastrointestinal Stromal Tumors by Ono Pharmaceutical Co. Ltd, this one is one of 2 that started in 2021, is one of 3 in phase 1/2, and was the 6th registered.

Gastrointestinal Stromal Tumors

343 studies on the registry are indexed under Gastrointestinal Stromal Tumors; 61 are open to participants now.

Browse Gastrointestinal Stromal Tumors studies →

Open to participants now

2 of the 10 studies in Gastrointestinal Stromal Tumors by Ono Pharmaceutical Co. Ltd are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 49 Gastrointestinal Stromal Tumors studies recruiting now, 38 (78%) set no upper age limit and 4 (8%) stop at 75 or younger; 6 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Gastrointestinal Stromal Tumors by Ono Pharmaceutical Co. Ltd, or all of them as a file.
02

Study summary

Multicenter, open-label Phase 1b/2 study of ripretinib in combination with binimetinib in patients with gastrointestinal stromal tumor (GIST). There will be 2 distinct parts in this study: Dose Escalation (Phase 1) and Expansion (Phase 2).

03

Conditions studied

  • Gastrointestinal Stromal Tumors
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients ≥18 years of age with advanced GIST (unresectable or ).
  2. Must have at least progressed on imatinib or have documented intolerance to imatinib.
  3. Patients must have an (ECOG) performance status (PS) of 0 or 1.
  4. Patients must have a histologic diagnosis of GIST.
  5. If a female of , must have a negative pregnancy test.
  6. Adequate organ function and bone marrow function

Exclusion criteria

Exclusion Criteria:

  1. Received prior anticancer therapy within 14 days or 5× the half-life whichever is longer) prior to the first dose.
  2. Ongoing or prior participation in the DCC-2618-03-002 study.
  3. Prior therapy with ripretinib.
  4. Prior therapy with MEK inhibitor.
  5. History of certain ocular disorders.
  6. History of hepatobiliary disease.
  7. Known active central nervous system .
  8. History or presence of clinically relevant cardiovascular abnormalities.
  9. Systemic arterial or venous thrombotic or embolic events within 6 months of first dose.
  10. History of acute or chronic pancreatitis
  11. History of chronic inflammatory bowel disease or Crohn's disease requiring intervention within 12 months of first dose.
  12. Gastrointestinal abnormalities including but not limited to:

    • inability to take oral medication,
    • malabsorption syndromes
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Escalation

    Escalation Phase: Increasing doses of ripretinib in combination with increase doses of binimetinib in patients with advanced GIST who have progressed on at least imatinib or are intolerant to imatinib and are ripretinib naïve in repeated 28-day cycles. Participants may remain on treatment until disease progression, unacceptable toxicity, or withdrawal of consent

    Drug: Ripretinib · Drug: binimetinib

  • Experimental
    Expansion

    Ripretinib in combination with binimetinib at the recommended Phase 2 dose (RP2D) in patients with advanced GIST who have progressed on imatinib or are intolerant to imatinib and are naïve. Participants may remain on treatment until disease progression, unacceptable toxicity, or withdrawal of consent

    Drug: Ripretinib · Drug: binimetinib

Interventions

  • 50 mg tablets

    Also known as: DCC-2618, QINLOCK

  • 15 mg tablets

    Also known as: Mektovi

06

What researchers measure

Primary outcomes

  1. Safety/tolerability of oral ripretinib in combination with binimetinib: incidence of adverse events

    Adverse events \[TEAEs, SAEs, AESIs\], dose reduction, dose interruption, or discontinuation, vital signs (heart rate \[beats/min\], and changes in laboratory parameters (chemistry, hematology, urinalysis, coagulation).

    Time frame: Approximately 12 months

  2. Determination of the Maximum Tolerated Dose and the Recommended Phase 2 Dose

    Time frame: Approximately 12 months

  3. Expansion Phase Only: Evaluate the objective response rate (ORR) of ripretinib in combination with binimetinib by modified RECIST

    Measure ORR

    Time frame: Approximately 36 months

Secondary outcomes

  1. Determine the time to maximum observed concentration (tmax) profile of oral ripretinib in combination with binimetinib

    Measure Tmax

    Time frame: Cycle 1 Day 1, and Cycle 1 Day15 (pre-dose and at multiple time points [up to 8 hours] post-dose). Each cycle is 28 days

  2. Determine the maximum observed concentration (Cmax) profile of oral ripretinib in combination with binimetinib

    Measure Cmax

    Time frame: Cycle 1 Day 1, and Cycle 1 Day15 (pre-dose and at multiple time points [up to 8 hours] post-dose). Each cycle is 28 days

  3. Determine the minimum observed concentration (Cmin) profile of oral ripretinib in combination with binimetinib

    Measure Cmin

    Time frame: Cycle 1 Day 1, and Cycle 1 Day15 (pre-dose and at multiple time points [up to 8 hours] post-dose). Each cycle is 28 days

  4. Determine the area under the concentration-time curve (AUC) profile of oral ripretinib in combination with binimetinib

    Measure AUC

    Time frame: Cycle 1 Day 1, and Cycle 1 Day15 (pre-dose and at multiple time points [up to 8 hours] post-dose). Each cycle is 28 days

  5. Evaluate the objective response rate (ORR) of ripretinib in combination with binimetinib by modified RECIST (escalation phase only) and Choi criteria (escalation and expansion phases)

    Measure ORR

    Time frame: Approximately 36 months

  6. Evaluate the progression-free survival (PFS) of ripretinib in combination with binimetinib

    Measure PFS

    Time frame: Approximately 36 months

  7. Evaluate the overall survival (OS) of ripretinib in combination with binimetinib

    Measure OS

    Time frame: Approximately 36 months

  8. Evaluate the duration of response (DOR) of ripretinib in combination with binimetinib

    Measure DOR

    Time frame: Approximately 36 months

  9. Evaluate the clinical benefit rate (CBR) of ripretinib in combination with binimetinib

    Measure CBR

    Time frame: Approximately 36 months

  10. Evaluate the time to response (TTR) of ripretinib in combination with binimetinib

    Measure TTR

    Time frame: Approximately 36 months

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Nov 2021; primary completion for Nov 2025, 48 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 20, 2021
First posted
Oct 18, 2021
StartEst.
Nov 2021
Primary completionEst.
Nov 2025
CompletionEst.
May 2027
Last update
Jan 5, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 5, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05080621
Responsible party
Sponsor
First posted
Oct 18, 2021
Start date
Nov 2021 (estimated)
Primary completion
Nov 2025 (estimated)
Completion
May 2027 (estimated)
Last update
Jan 5, 2022

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Dec 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ripretinib · Binimetinib

Start the discussion